# Daiichi Sankyo

Daiichi Sankyo is a Corporate Investor based in Tokyo, Japan.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Tokyo, Japan
- **Region:** Asia
- **Address:** 3-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan
- **Founded:** 2005
- **Assets under management:** Undisclosed
- **Website:** daiichisankyo.co.jp
- **LinkedIn:** https://www.linkedin.com/company/daiichi-sankyo-co-ltd-
- **Wikidata:** Q669441

## Regulatory record

- **Reports private funds:** No

## About

Daiichi Sankyo was formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo. Hiroyuki Okuzawa serves as Representative Director, President and CEO. The firm allocates resources primarily to pharmaceutical development and commercialization. It maintains strategic collaborations with AstraZeneca on Enhertu and with Merck on oncology trials. Geographic reach includes headquarters functions in Tokyo plus European operations in Munich and US operations in Basking Ridge, New Jersey. Asset classes center on direct project funding, clinical-stage assets and manufacturing facilities rather than external fund commitments or co-investments. No recent operational events from the last 24 months appear in available records. The company lists three philanthropic vehicles: Daiichi Sankyo Foundation of Life Science, Japan Research Foundation for Clinical Pharmacology and Manpei Suzuki Diabetes Foundation. Additional production sites operate in Pfaffenhofen, Germany and Altkirch, France. Daiichi Sankyo functions as a listed corporate entity whose investment activity remains tied to its core pharmaceutical mandate and partnership agreements.

## Sectors

- Healthcare Services

## Offices

- Munich, Germany
- Basking Ridge, New Jersey, USA

## People

- Hiroyuki Okuzawa — Representative Director, President and CEO

## Questions

### Who runs investment decisions at Daiichi Sankyo?

Hiroyuki Okuzawa serves as Representative Director, President and CEO. Capital allocation decisions remain integrated with the company's pharmaceutical development and partnership activities.

### Does Daiichi Sankyo participate in fund commitments or only direct deals?

Available information shows participation through direct collaborations and internal project funding. No external fund commitments are disclosed.

### Which sectors does Daiichi Sankyo explicitly avoid?

No explicit avoidance sectors are stated in public records. Activity centers on pharmaceutical research, development and commercialization.

### How is Daiichi Sankyo related to its listed partnerships?

The firm maintains ongoing collaborations with AstraZeneca and Merck focused on oncology assets. A prior partnership with Sun Pharmaceutical Industries ended with the 2014 sale of Ranbaxy.

## Related profiles

- [Dai-ichi Life Insurance](https://altss.com/profile/dai-ichi-life-insurance)
- [Daiken Corporate Pension Fund](https://altss.com/profile/daiken-corporate-pension-fund)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/daiichi-sankyo

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology